更新于：2024-11-21

Amiprilose hydrochloride

更新于：2024-11-21

概要

研发状态

概要

基本信息

药物类型

小分子化药

别名

Amiprilose hydrochloride (USAN)

+ [3]

靶点-

作用机制

免疫调节剂

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

类风湿关节炎

原研机构

Alseres Pharmaceuticals, Inc.

在研机构-

非在研机构

Alseres Pharmaceuticals, Inc.

最高研发阶段终止申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C14H28ClNO6

InChIKeyRJNRORZRFGUAKL-ADMBVFOFSA-N

CAS号60414-06-4

查看全部结构式(2)

关联

100 项与 Amiprilose hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Amiprilose hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Amiprilose hydrochloride 相关的专利（医药）

登录后查看更多信息

项与 Amiprilose hydrochloride 相关的文献（医药）

2020-10-01·Cancer Medicine3区 · 医学

Identification of potential prognostic small nucleolar RNA biomarkers for predicting overall survival in patients with sarcoma

3区 · 医学

ArticleOA

作者: Liu, Jianwei ; Lv, Peizhen ; Zhu, Xianze ; Li, Rong ; Liao, Xiwen

AbstractObjectiveThe main purpose of the present study is to screen prognostic small nucleolar RNA (snoRNA) markers using the RNA‐sequencing (RNA‐seq) dataset of The Cancer Genome Atlas (TCGA) sarcoma cohort.MethodsThe sarcoma RNA‐seq dataset comes from the TCGA cohort. A total of 257 sarcoma patients were included into the prognostic analysis. Multiple bioinformatics analysis methods for functional annotation of snoRNAs and screening of targeted drugs, including biological network gene ontology tool, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and connectivity map (CMap) are used.ResultsWe had identified 15 snoRNAs that were significantly related to the prognosis of sarcoma and constructed a prognostic signature based on four prognostic snoRNA (U3, SNORA73B, SNORD46, and SNORA26) expression values. Functional annotation of these four snoRNAs by their co‐expression genes suggests that some of them were closely related to cell cycle‐related biological processes and tumor‐related signaling pathways, such as Wnt, mitogen‐activated protein kinase, target of rapamycin, and nuclear factor‐kappa B signaling pathway. GSEA of the risk score suggests that high risk score phenotype was significantly enriched in cell cycle‐related biological processes, protein SUMOylation, DNA replication, p53 binding, regulation of DNA repair, and DNA methylation, as well as Myc, Wnt, RB1, E2F, and TEL pathways. Then we also used the CMap online tool to screen five targeted drugs (rilmenidine, pizotifen, amiprilose, quipazine, and cinchonidine) for this risk score model in sarcoma.ConclusionOur study have identified 15 snoRNAs that may be serve as novel prognostic biomarkers for sarcoma, and constructed a prognostic signature based on four prognostic snoRNA expression values.

2020-01-01·Journal of Cancer3区 · 医学

Clinical significance of long non-coding RNA DUXAP8 and its protein coding genes in hepatocellular carcinoma

3区 · 医学

ArticleOA

作者: Yang, Cheng-Kun ; Wang, Xiang-Kun ; Zhou, Xin ; Peng, Tao ; Chen, Zi-Jun ; Huang, Rui ; Huang, Jian-Lu ; Liao, Xi-Wen ; Zhu, Guang-Zhi ; Han, Chuang-Ye

Backgrounds: Hepatocellular carcinoma (HCC) is a lethal malignancy worldwide that is difficult to diagnose during the early stages and its tumors are recurrent. Long non-coding RNAs (lncRNAs) have increasingly been associated with tumor biomarkers for diagnosis and prognosis. This study attempts to explore the potential clinical significance of lncRNA DUXAP8 and its co-expression related protein coding genes (PCGs) for HCC. Method: Data from a total of 370 HCC patients from The Cancer Genome Atlas were utilized for the analysis. DUXAP8 and its top 10 PCGs were explored for their diagnostic and prognostic implications for HCC. A risk score model and nomogram were constructed for prognosis prediction using prognosis-related genes and DUXAP8. Molecular mechanisms of DUXAP8 and its PCGs involved in HCC initiation and progression were investigated. Then, potential target drugs were identified using genome-wide DUXAP8-related differentially expressed genes in a Connectivity Map database. Results: The top 10 PCGs were identified as: RNF2, MAGEA1, GABRA3, MKRN3, FAM133A, MAGEA3, CNTNAP4, MAGEA6, MALRD1, and DGKI. Diagnostic analysis indicated that DUXAP8, MEGEA1, MKRN3, and DGKI show diagnostic implications (all area under curves ≥0.7, p≤0.05). Prognostic analysis indicated that DUXAP8 and RNF2 had prognostic implications for HCC (adjusted p=0.014 and 0.008, respectively). The risk score model and nomogram showed an advantage for prognosis prediction. A total of 3 target drugs were determined: cinchonine, bumetanide and amiprilose and they may serve as potential therapeutic targets for HCC. Conclusion: Functioning as an oncogene, DUXAP8 is overexpressed in tumor tissue and may serve as both a diagnostic and prognosis biomarker for HCC. MEGEA1, MKRN3, and DGKI maybe potential diagnostic biomarkers and DGKI may also be potentially prognostic biomarkers for HCC.

2000-02-01·JCR: Journal of Clinical Rheumatology4区 · 医学

Amiprilose Hydrochloride for the Treatment of Rheumatoid Arthritis

4区 · 医学

Article

作者: Beverly A. Carpenter ; Marc E. Lanser ; Rose S. Fife ; David E. Trentham ; Jane Herron Box ; Richard Trout

The intent of this study was to compare, in a monotherapy framework, an optimal dose of the synthetic hexose sugar, amiprilose hydrochloride (HCl), to a placebo in the treatment of rheumatoid arthritis. In this double-blind, randomized, multi-center study, patients first underwent a washout period from disease-modifying antirheumatic drugs. Those who subsequently met flare criteria within 14 days of discontinuing previously stable doses of nonsteroidal anti-inflammatory drugs were randomized to amiprilose HCl (103 patients) or a placebo (115 patients) for the subsequent 20 weeks. Glucocorticoid or nonsteroidal anti-inflammatory drugs use was not permitted. At the baseline, demographic and disease characteristics were similar in both groups. Of patients completing the course of therapy, 73% were in the amiprilose HCl group and 66% were in the placebo group. Using an intent-to-treat analysis, numeric trends favoring amiprilose HCl treatment were found for clinical and laboratory parameters of disease activity. Compared with the placebo group, statistically significant degrees of improvement were achieved for the number of swollen joints (p /= \50% reduction in swollen joints (p

100 项与 Amiprilose hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02911	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
类风湿关节炎	申请上市	荷兰	-	-
类风湿关节炎	申请上市	英国	-	-
类风湿关节炎	申请上市	美国	-	-
类风湿关节炎	申请上市	法国	-	-
类风湿关节炎	申请上市	瑞士	-	-
类风湿关节炎	申请上市	-	Alseres Pharmaceuticals, Inc.	-
类风湿关节炎	申请上市	爱尔兰	-	-